Carcinogenesis and cancer prevention: the process and the disease deserve a better understanding by Kovvali, Gopala
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
Journal of Carcinogenesis
Open Access Journal of Carcinogenesis  2002,  1 x Editorial
Carcinogenesis and cancer prevention: the process and the disease 
deserve a better understanding
Gopala Kovvali
Address: Crohn's and Colitis Center of New Jersey, Department of Medicine, The University of Medicine and Dentistry of New Jersey Room 7023, 
125 Paterson Street, Clinical Academic Building, New Brunswick NJ 08901, United States
E-mail: kovvalgk@umdnj.edu
The last few decades have seen a significant progress in the
management of various cancers. In addition to traditional
treatments such as radiation, surgery, and chemotherapy,
several new approaches based on knowledge of biological
processes have been developed and tested and are being
constantly refined. It is ironic that while we are making
progress in treating cancers, the incidence of cancers is in-
creasing. This discomforting fact suggests that perhaps the
best way to fight cancer may be to prevent it from appear-
ing in the first place.
A common question in the minds of scientists and physi-
cians involved in research and treatment of cancer is how
do we prevent it? The obvious answer comes from the age
old saying that 'you are what you eat and breathe, and that
in turn may answer the question of how our ancestors had
much lower incidence of cancer.
As we, the scientists, are curious, we ask what are the sub-
stances in our food that are vital to maintain normal func-
tioning of the cells in the body? A corollary to this
question would be, could we identify those substances
and supplement them into food to prevent and or reverse
the process of cancer development.
The possibility of reversing cancer depends on the knowl-
edge of the fundamental molecular changes that accom-
pany the process of cancer development. The paradigm
that cancer is a result of genetic changes and is, therefore,
not amenable to efforts to reverse it, seems to be giving
way to a new concept that 'genetic changes are not neces-
sarily permanently etched in cells and the wild type char-
acteristics of the cells could be restored'. Results published
in recent papers are encouraging and show a promise for
a major paradigm shift [1–8].
Incidence of cancers of the gastrointestinal tract is increas-
ing at an alarming rate. It is important to develop non-in-
vasive methods of detecting precancerous and cancerous
lesions. Development of sensitive and specific techniques
for early diagnosis will have a far-reaching effect on reduc-
ing the incidence of and mortality from GI cancers in at-
risk population.
Technological advances in the field of genomics and pro-
teomics are responsible for a major thrust in understand-
ing the complex molecular processes of cancer and for
assessing the efficacy of various compounds-natural prod-
ucts and synthetic analogues. Complete sequencing of the
human genome and identification of all human genes in
near future will have far reaching influence on our under-
standing of complex processes like cancer and will lead to
effective therapies.
In spite of all these advances in the treatment of cancer
and knowledge of the processes responsible for the dis-
ease, there is a gap in the understanding of molecular
events leading to cancer and mechanisms of action by an-
ticancer agents. Generally speaking, the field of carcino-
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genesis is far from being completely explored. Many novel
ideas and concepts still need to be introduced into the
field and the results of several provocative experiments are
yet to be disseminated and shared. There is a need and
greater scope for multidisciplinary research in the field. A
forum for an accelerated publication of results and a free
access to such publications is very important to the field.
These are the considerations that led to the birth of a new
online journal, Journal of Carcinogenesis.
I am very happy that several eminent researchers and phy-
sicians have agreed to be on the editorial board of this
journal. The journal will branch into six sections headed
by an editor who is an expert in that field. Steven Shiff will
be in charge of organizing the section on diet and environ-
mental carcinogenesis, Nitin Telang will be editor for Che-
moprevention section, Yutaka Kohgo will head clinical
and Preclinical studies, Hongua Li will edit Genomics and
Proteomics, Kiron Das will edit a section on gastrointesti-
nal carcinogenesis and Satya Narayan will be editing a sec-
tion on DNA damage response and cell signaling.
I hope the new journal will receive your support and sug-
gestions and you will consider it a journal worthy of pub-
lishing your exciting results.
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